📰 Activmab Platform Technology News
Activmab Platform Technology News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Activmab Platform Technology. Real-time updates on events, politics, business and more.
April 3, 2023
03.04.2023 - Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for a pre-planned interim analysis of KEYNOTE B84 ...
November 14, 2022
14.11.2022 - Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient ...
August 15, 2022
Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell...
August 15, 2022
15.08.2022 - Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in Nature Medicine Patient enrollment continues in ...